Intra-Cellular Therapies (ITCI) – Analysts’ Weekly Ratings Updates

Intra-Cellular Therapies (NASDAQ: ITCI) recently received a number of ratings updates from brokerages and research firms:

• 3/12/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/4/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/24/2025 – Intra-Cellular Therapies was downgraded by analysts at Mizuho from an “outperform” rating to a “neutral” rating. They now have a $132.00 price target on the stock, down previously from $140.00.
• 2/24/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/21/2025 – Intra-Cellular Therapies had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 2/16/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/8/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/31/2025 – Intra-Cellular Therapies was downgraded by analysts at Canaccord Genuity Group Inc. from a “buy” rating to a “hold” rating. They now have a $132.00 price target on the stock, up previously from $119.00.
• 1/31/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/23/2025 – Intra-Cellular Therapies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/22/2025 – Intra-Cellular Therapies had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $132.00 price target on the stock, up previously from $108.00.
• 1/14/2025 – Intra-Cellular Therapies was upgraded by analysts at Cantor Fitzgerald from a “hold” rating to a “strong-buy” rating.
• 1/14/2025 – Intra-Cellular Therapies had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $132.00 price target on the stock, up previously from $107.00.
• 1/13/2025 – Intra-Cellular Therapies was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 1/13/2025 – Intra-Cellular Therapies was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 1/13/2025 – Intra-Cellular Therapies had its “hold” rating reaffirmed by analysts at Needham & Company LLC. They now have a $100.00 price target on the stock.

Intra-Cellular Therapies Stock Down 0.0 %

Shares of ITCI traded down $0.00 during mid-day trading on Thursday, hitting $131.25. The company had a trading volume of 1,216,335 shares, compared to its average volume of 1,317,651. The stock has a market cap of $13.96 billion, a PE ratio of -150.86 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1-year low of $63.30 and a 1-year high of $131.37. The business’s 50-day simple moving average is $122.06 and its 200-day simple moving average is $94.74.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. On average, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ITCI. China Universal Asset Management Co. Ltd. boosted its stake in Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC grew its holdings in shares of Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after buying an additional 25,435 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Intra-Cellular Therapies by 31.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock valued at $33,258,000 after buying an additional 109,892 shares in the last quarter. Oak Ridge Investments LLC raised its position in Intra-Cellular Therapies by 74.1% during the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after buying an additional 8,440 shares during the period. Finally, Cynosure Group LLC lifted its stake in Intra-Cellular Therapies by 161.0% in the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock worth $1,057,000 after acquiring an additional 8,909 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.